Pulse Biosciences (NASDAQ: PLSE) stock is soaring 6.26% in pre-market trading on Friday following the release of its fourth-quarter 2024 earnings report and conference call. The company, which specializes in developing nanosecond pulsed field ablation (nsPFA) technology, highlighted several positive developments that have boosted investor confidence.

During the earnings call, CEO Paul Laviolette emphasized the company's progress in commercializing its percutaneous electrode for benign thyroid diseases and advancing clinical feasibility studies for atrial fibrillation treatments. Pulse Biosciences has received seven FDA clearances and treated 6,000 patients, demonstrating the maturity of its nsPFA platform. The company's technology is protected by over 180 issued patents, positioning it as a leader in the next generation of pulse field ablation.

Financial highlights include a strengthened balance sheet, with cash and cash equivalents totaling $118 million as of December 31, 2024, compared to $44.4 million the previous year. This increase was largely due to $47.9 million raised through warrant exercises in the fourth quarter. While the company reported increased losses, investors appear to be focusing on the potential of Pulse Biosciences' technology and its future growth prospects.

Looking ahead, Pulse Biosciences plans to initiate IDE pivotal studies for its cardiac 360 catheter and cardiac surgical clamp in 2025. The company is also implementing a hybrid business model for market entry, which could accelerate the adoption of its nsPFA technology across multiple clinical applications. With these developments and a strong cash position, investors seem optimistic about Pulse Biosciences' ability to capitalize on the growing market for advanced medical technologies.